🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

33 results for “Prime” Clear

  1. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial

  2. PG-011 nasal spray 0.6%(twice daily)

    Prime Medicine

    Seasonal Allergic Rhinitis

    phase 3 small molecule active

    1 trial

  3. PG-011Gel

    Prime Medicine

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  4. Recommended treatment schedule

    Prime Medicine

    COVID-19

    phase 3 small molecule terminated

    1 trial

  5. BCMA targeted prime CAR-T cells

    PRECISION BIOSCIENCES INC

    Multiple Myeloma

    phase 2 mab active

    1 trial

  6. Bemarituzumab

    Prime Medicine

    Gastric Cancer

    phase 2 mab completed

    1 trial

  7. CD19 and CD22 targeted prime CAR- T cells

    PRECISION BIOSCIENCES INC

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  8. CD19 and CD22 targeted prime CAR-T cells

    PRECISION BIOSCIENCES INC

    B-ALL

    phase 2 mab active

    1 trial

  9. DNA vaccine prime

    United Therapeutics Europe Ltd

    Malaria

    phase 2 mab completed

    1 trial

  10. FP-1039

    Prime Medicine

    Endometrial Cancers With FGFR2 Mutations

    phase 2 small molecule terminated

    1 trial

  11. FPA008

    Prime Medicine

    Pigmented Villonodular Synovitis

    phase 2 mab completed

    1 trial

  12. KALINOX 50%/50%, gaz medicinal comprime, Medical Air

    Tour Hekla

    psychiatry

    phase 2 small molecule active

    1 trial

  13. KALINOX 50%/50%, gaz medicinal comprime, Medical Air

    Tour Hekla

    Treatment of suicidal ideation

    phase 2 small molecule active

    1 trial

  14. Medtronic PrimeADVANCED Neurostimulator

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    phase 2 other completed

    1 trial

  15. PM359

    Prime Medicine

    Chronic Granulomatous Disease

    phase 2 mab active

    1 trial

  16. PrimeC

    NeuroSense Therapeutics

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  17. PrimeC

    NeuroSense Therapeutics

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  18. Pumecitinib Nasal Spray 0.3%

    Prime Medicine

    Seasonal Allergic Rhinitis

    phase 2 small molecule active

    1 trial

  19. Xeloda 150 mg film-coated tablets, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic colorectal adenocarcinoma

    phase 2 small molecule active

    1 trial

  20. Bemarituzumab

    Prime Medicine

    Gastrointestinal Cancer

    phase 1 mab completed

    1 trial

  21. Cabiralizumab

    Prime Medicine

    Advanced Solid Tumors

    phase 1 mab completed

    1 trial

  22. FP-1039

    Prime Medicine

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  23. FPA008

    Prime Medicine

    Healthy

    phase 1 small molecule terminated

    1 trial

  24. FPA144

    Prime Medicine

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources